Sign In

Login

Password

Forgot Password ? Sign Up

Inhibitory pompy protonowej (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Inhibitory pompy protonowej" in Polish language version.

refsWebsite
Global rank Polish rank
30nih.gov
4th place
7th place
28doi.org
2nd place
6th place
2mp.pl
8,738th place
165th place
1home.pl
low place
367th place
1tropicalgastro.com
low place
low place
1lww.com
2,769th place
1,863rd place
1worldcat.org
5th place
2nd place
1archive.is
87th place
5th place
1leki.pl
low place
low place

archive.is

doi.org

dx.doi.org

  • Vandana Boparai, Jaishree Rajagopalan, George Triadafilopoulos, Guide to the use of proton pump inhibitors in adult patients, „Drugs”, 68 (7), 2008, s. 925–947, DOI: 10.2165/00003495-200868070-00004, PMID: 18457460 [dostęp 2022-01-17] (ang.). Komentarz: Witold Bartnik, Przewodnik stosowania inhibitorów pompy protonowej u dorosłych, Medycyna Praktyczna, 2009 [dostęp 2022-01-17].
  • C.W. Howden, Clinical pharmacology of omeprazole, „Clinical Pharmacokinetics”, 20 (1), 1991, s. 38–49, DOI: 10.2165/00003088-199120010-00003, PMID: 2029801 [dostęp 2022-01-17] (ang.).
  • L. Laine, D. Ahnen, C. McClain, E. Solcia, J.H. Walsh, Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors, „Alimentary Pharmacology & Therapeutics”, 14 (6), 2000, s. 651–668, DOI: 10.1046/j.1365-2036.2000.00768.x, PMID: 10848649 [dostęp 2022-01-17] (ang.).
  • Khek Yu Ho i inni, Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers, „Journal of Gastroenterology”, 44 (7), 2009, s. 697–707, DOI: 10.1007/s00535-009-0072-4, PMID: 19434360 [dostęp 2022-01-17] (ang.).
  • Elaine Chong, Mary H.H. Ensom, Pharmacogenetics of the proton pump inhibitors: a systematic review, „Pharmacotherapy”, 23 (4), 2003, s. 460–471, DOI: 10.1592/phco.23.4.460.32128, PMID: 12680476 [dostęp 2022-01-17] (ang.).
  • L.B. Gerson, G. Triadafilopoulos, Proton pump inhibitors and their drug interactions: an evidence-based approach, „European Journal of Gastroenterology & Hepatology”, 13 (5), 2001, s. 611–616, DOI: 10.1097/00042737-200105000-00025, PMID: 11396546 [dostęp 2022-01-17] (ang.).
  • Ian J. Simpson i inni, Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases, „Nephrology”, 11 (5), 2006, s. 381–385, DOI: 10.1111/j.1440-1797.2006.00651.x, PMID: 17014549 [dostęp 2022-01-17] (ang.).
  • E.J. Kuipers i inni, Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication, „The New England Journal of Medicine”, 334 (16), 1996, s. 1018–1022, DOI: 10.1056/NEJM199604183341603, PMID: 8598839 [dostęp 2022-01-17] (ang.).
  • Robert J.F. Laheij i inni, Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs, „Journal of the American Medical Association”, 292 (16), 2004, s. 1955–1960, DOI: 10.1001/jama.292.16.1955, PMID: 15507580 [dostęp 2022-01-17] (ang.).
  • Sandra Dial, Khalid Alrasadi, Chantal Manoukian, Allen Huang, Dick Menzies, Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies, „Canadian Medical Association Journal”, 171 (1), 2004, s. 33–38, DOI: 10.1503/cmaj.1040876, PMID: 15238493, PMCID: PMC437681 [dostęp 2022-01-17] (ang.).
  • Jennifer Leonard, John K. Marshall, Paul Moayyedi, Systematic review of the risk of enteric infection in patients taking acid suppression, „The American Journal of Gastroenterology”, 102 (9), 2007, 2047–2056; quiz 2057, DOI: 10.1111/j.1572-0241.2007.01275.x, PMID: 17509031 [dostęp 2022-01-17] (ang.).
  • Yu-Xiao Yang, James D. Lewis, Solomon Epstein, David C. Metz, Long-term proton pump inhibitor therapy and risk of hip fracture, „Journal of the American Medical Association”, 296 (24), 2006, s. 2947–2953, DOI: 10.1001/jama.296.24.2947, PMID: 17190895 [dostęp 2022-01-17] (ang.).
  • S.A. Watson i inni, Potential role of endocrine gastrin in the colonic adenoma carcinoma sequence, „British Journal of Cancer”, 87 (5), 2002, s. 567–573, DOI: 10.1038/sj.bjc.6600509, PMID: 12189558, PMCID: PMC2376163 [dostęp 2022-01-17] (ang.).
  • F.W. Green, M.M. Kaplan, L.E. Curtis, P.H. Levine, Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage, „Gastroenterology”, 74 (1), 1978, s. 38–43, DOI: 10.1016/0016-5085(78)90352-9, PMID: 21830 [dostęp 2022-01-17] (ang.).
  • J. Mark Ruscin, Robert Lee Page, Robert J. Valuck, Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor, „The Annals of Pharmacotherapy”, 36 (5), 2002, s. 812–816, DOI: 10.1345/aph.10325, PMID: 11978157 [dostęp 2022-01-17] (ang.).
  • Henning Blume, Frank Donath, André Warnke, Barbara S. Schug, Pharmacokinetic drug interaction profiles of proton pump inhibitors, „Drug Safety”, 29 (9), 2006, s. 769–784, DOI: 10.2165/00002018-200629090-00002, PMID: 16944963 [dostęp 2022-01-17] (ang.).
  • T.J. Humphries, Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole, „Digestive Diseases and Sciences”, 36 (12), 1991, s. 1665–1669, DOI: 10.1007/BF01296606, PMID: 1748033 [dostęp 2022-01-17] (ang.).
  • R.K. Dixit, A.B. Chawla, N. Kumar, S.K. Garg, Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers, „Methods and Findings in Experimental and Clinical Pharmacology”, 23 (1), 2001, s. 37–39, DOI: 10.1358/mf.2001.23.1.619178, PMID: 11413862 [dostęp 2022-01-17] (ang.).
  • J. De Graef, M.C. Woussen-Colle, Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs, „Gastroenterology”, 91 (2), 1986, s. 333–337, DOI: 10.1016/0016-5085(86)90565-2, PMID: 2873074 [dostęp 2022-01-17] (ang.).
  • Jesper Hallas i inni, Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study, „BMJ (Clinical research ed.)”, 333 (7571), 2006, s. 726, DOI: 10.1136/bmj.38947.697558.AE, PMID: 16984924, PMCID: PMC1592384 [dostęp 2022-01-17] (ang.).
  • Angel Lanas i inni, Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants, „The American Journal of Gastroenterology”, 102 (3), 2007, s. 507–515, DOI: 10.1111/j.1572-0241.2006.01062.x, PMID: 17338735 [dostęp 2022-01-17] (ang.).
  • Deepak L. Bhatt i inni, ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, „Journal of the American College of Cardiology”, 52 (18), 2008, s. 1502–1517, DOI: 10.1016/j.jacc.2008.08.002, PMID: 19017521 [dostęp 2022-01-17] (ang.).
  • M. Gilard, B. Arnaud, G. Le Gal, J.F. Abgrall, J. Boschat, Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin, „Journal of Thrombosis and Haemostasis”, 4 (11), 2006, s. 2508–2509, DOI: 10.1111/j.1538-7836.2006.02162.x, PMID: 16898956 [dostęp 2022-01-17] (ang.).
  • Martine Gilard i inni, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study, „Journal of the American College of Cardiology”, 51 (3), 2008, s. 256–260, DOI: 10.1016/j.jacc.2007.06.064, PMID: 18206732 [dostęp 2022-01-17] (ang.).
  • David N. Juurlink i inni, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel, „Canadian Medical Association journal”, 180 (7), 2009, s. 713–718, DOI: 10.1503/cmaj.082001, PMID: 19176635, PMCID: PMC2659819 [dostęp 2022-01-17] (ang.).
  • Edmund Pezalla, David Day, Indira Pulliadath, Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors, „Journal of the American College of Cardiology”, 52 (12), 2008, 1038–1039; author reply 1039, DOI: 10.1016/j.jacc.2008.05.053, PMID: 18786491 [dostęp 2022-01-17] (ang.).
  • Xue-Qing Li, Tommy B. Andersson, Marie Ahlström, Lars Weidolf, Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities, „Drug Metabolism and Disposition: The Biological Fate of Chemicals”, 32 (8), 2004, s. 821–827, DOI: 10.1124/dmd.32.8.821, PMID: 15258107 [dostęp 2022-01-17] (ang.).
  • Paul Moayyedi, Daniel C. Sadowski, Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data?, „Canadian Journal of Gastroenterology”, 23 (4), 2009, s. 251–252, DOI: 10.1155/2009/868946, PMID: 19373416, PMCID: PMC2711671 [dostęp 2022-01-17] (ang.).

home.pl

script.home.pl

leki.pl

lww.com

journals.lww.com

mp.pl

nih.gov

ncbi.nlm.nih.gov

  • Vandana Boparai, Jaishree Rajagopalan, George Triadafilopoulos, Guide to the use of proton pump inhibitors in adult patients, „Drugs”, 68 (7), 2008, s. 925–947, DOI: 10.2165/00003495-200868070-00004, PMID: 18457460 [dostęp 2022-01-17] (ang.). Komentarz: Witold Bartnik, Przewodnik stosowania inhibitorów pompy protonowej u dorosłych, Medycyna Praktyczna, 2009 [dostęp 2022-01-17].
  • George Sachs, Jai Moo Shin, The basis of differentiation of PPIs, „Drugs of Today (Barcelona, Spain: 1998)”, 40 Suppl A, 2004, s. 9–14, PMID: 15190382 [dostęp 2022-01-17] (ang.).
  • C.W. Howden, Clinical pharmacology of omeprazole, „Clinical Pharmacokinetics”, 20 (1), 1991, s. 38–49, DOI: 10.2165/00003088-199120010-00003, PMID: 2029801 [dostęp 2022-01-17] (ang.).
  • L. Laine, D. Ahnen, C. McClain, E. Solcia, J.H. Walsh, Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors, „Alimentary Pharmacology & Therapeutics”, 14 (6), 2000, s. 651–668, DOI: 10.1046/j.1365-2036.2000.00768.x, PMID: 10848649 [dostęp 2022-01-17] (ang.).
  • Khek Yu Ho i inni, Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers, „Journal of Gastroenterology”, 44 (7), 2009, s. 697–707, DOI: 10.1007/s00535-009-0072-4, PMID: 19434360 [dostęp 2022-01-17] (ang.).
  • Elaine Chong, Mary H.H. Ensom, Pharmacogenetics of the proton pump inhibitors: a systematic review, „Pharmacotherapy”, 23 (4), 2003, s. 460–471, DOI: 10.1592/phco.23.4.460.32128, PMID: 12680476 [dostęp 2022-01-17] (ang.).
  • L.B. Gerson, G. Triadafilopoulos, Proton pump inhibitors and their drug interactions: an evidence-based approach, „European Journal of Gastroenterology & Hepatology”, 13 (5), 2001, s. 611–616, DOI: 10.1097/00042737-200105000-00025, PMID: 11396546 [dostęp 2022-01-17] (ang.).
  • Ian J. Simpson i inni, Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases, „Nephrology”, 11 (5), 2006, s. 381–385, DOI: 10.1111/j.1440-1797.2006.00651.x, PMID: 17014549 [dostęp 2022-01-17] (ang.).
  • Dipti Chourasia, Asha Misra, Rakesh Pandey, Uday C. Ghoshal, Gastric atrophy and intestinal metaplasia in a patient on long-term proton pump inhibitor therapy, „Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation”, 29 (3), 2008, s. 172–174, PMID: 19115612 [dostęp 2022-01-17] (ang.).
  • E.J. Kuipers i inni, Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication, „The New England Journal of Medicine”, 334 (16), 1996, s. 1018–1022, DOI: 10.1056/NEJM199604183341603, PMID: 8598839 [dostęp 2022-01-17] (ang.).
  • Robert J.F. Laheij i inni, Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs, „Journal of the American Medical Association”, 292 (16), 2004, s. 1955–1960, DOI: 10.1001/jama.292.16.1955, PMID: 15507580 [dostęp 2022-01-17] (ang.).
  • Sandra Dial, Khalid Alrasadi, Chantal Manoukian, Allen Huang, Dick Menzies, Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies, „Canadian Medical Association Journal”, 171 (1), 2004, s. 33–38, DOI: 10.1503/cmaj.1040876, PMID: 15238493, PMCID: PMC437681 [dostęp 2022-01-17] (ang.).
  • Jennifer Leonard, John K. Marshall, Paul Moayyedi, Systematic review of the risk of enteric infection in patients taking acid suppression, „The American Journal of Gastroenterology”, 102 (9), 2007, 2047–2056; quiz 2057, DOI: 10.1111/j.1572-0241.2007.01275.x, PMID: 17509031 [dostęp 2022-01-17] (ang.).
  • Yu-Xiao Yang, James D. Lewis, Solomon Epstein, David C. Metz, Long-term proton pump inhibitor therapy and risk of hip fracture, „Journal of the American Medical Association”, 296 (24), 2006, s. 2947–2953, DOI: 10.1001/jama.296.24.2947, PMID: 17190895 [dostęp 2022-01-17] (ang.).
  • S.A. Watson i inni, Potential role of endocrine gastrin in the colonic adenoma carcinoma sequence, „British Journal of Cancer”, 87 (5), 2002, s. 567–573, DOI: 10.1038/sj.bjc.6600509, PMID: 12189558, PMCID: PMC2376163 [dostęp 2022-01-17] (ang.).
  • F.W. Green, M.M. Kaplan, L.E. Curtis, P.H. Levine, Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage, „Gastroenterology”, 74 (1), 1978, s. 38–43, DOI: 10.1016/0016-5085(78)90352-9, PMID: 21830 [dostęp 2022-01-17] (ang.).
  • J. Mark Ruscin, Robert Lee Page, Robert J. Valuck, Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor, „The Annals of Pharmacotherapy”, 36 (5), 2002, s. 812–816, DOI: 10.1345/aph.10325, PMID: 11978157 [dostęp 2022-01-17] (ang.).
  • Henning Blume, Frank Donath, André Warnke, Barbara S. Schug, Pharmacokinetic drug interaction profiles of proton pump inhibitors, „Drug Safety”, 29 (9), 2006, s. 769–784, DOI: 10.2165/00002018-200629090-00002, PMID: 16944963 [dostęp 2022-01-17] (ang.).
  • T.J. Humphries, Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole, „Digestive Diseases and Sciences”, 36 (12), 1991, s. 1665–1669, DOI: 10.1007/BF01296606, PMID: 1748033 [dostęp 2022-01-17] (ang.).
  • R.K. Dixit, A.B. Chawla, N. Kumar, S.K. Garg, Effect of omeprazole on the pharmacokinetics of sustained-release carbamazepine in healthy male volunteers, „Methods and Findings in Experimental and Clinical Pharmacology”, 23 (1), 2001, s. 37–39, DOI: 10.1358/mf.2001.23.1.619178, PMID: 11413862 [dostęp 2022-01-17] (ang.).
  • J. De Graef, M.C. Woussen-Colle, Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs, „Gastroenterology”, 91 (2), 1986, s. 333–337, DOI: 10.1016/0016-5085(86)90565-2, PMID: 2873074 [dostęp 2022-01-17] (ang.).
  • Jesper Hallas i inni, Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study, „BMJ (Clinical research ed.)”, 333 (7571), 2006, s. 726, DOI: 10.1136/bmj.38947.697558.AE, PMID: 16984924, PMCID: PMC1592384 [dostęp 2022-01-17] (ang.).
  • Angel Lanas i inni, Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants, „The American Journal of Gastroenterology”, 102 (3), 2007, s. 507–515, DOI: 10.1111/j.1572-0241.2006.01062.x, PMID: 17338735 [dostęp 2022-01-17] (ang.).
  • Deepak L. Bhatt i inni, ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, „Journal of the American College of Cardiology”, 52 (18), 2008, s. 1502–1517, DOI: 10.1016/j.jacc.2008.08.002, PMID: 19017521 [dostęp 2022-01-17] (ang.).
  • M. Gilard, B. Arnaud, G. Le Gal, J.F. Abgrall, J. Boschat, Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin, „Journal of Thrombosis and Haemostasis”, 4 (11), 2006, s. 2508–2509, DOI: 10.1111/j.1538-7836.2006.02162.x, PMID: 16898956 [dostęp 2022-01-17] (ang.).
  • Martine Gilard i inni, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study, „Journal of the American College of Cardiology”, 51 (3), 2008, s. 256–260, DOI: 10.1016/j.jacc.2007.06.064, PMID: 18206732 [dostęp 2022-01-17] (ang.).
  • David N. Juurlink i inni, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel, „Canadian Medical Association journal”, 180 (7), 2009, s. 713–718, DOI: 10.1503/cmaj.082001, PMID: 19176635, PMCID: PMC2659819 [dostęp 2022-01-17] (ang.).
  • Edmund Pezalla, David Day, Indira Pulliadath, Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors, „Journal of the American College of Cardiology”, 52 (12), 2008, 1038–1039; author reply 1039, DOI: 10.1016/j.jacc.2008.05.053, PMID: 18786491 [dostęp 2022-01-17] (ang.).
  • Xue-Qing Li, Tommy B. Andersson, Marie Ahlström, Lars Weidolf, Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities, „Drug Metabolism and Disposition: The Biological Fate of Chemicals”, 32 (8), 2004, s. 821–827, DOI: 10.1124/dmd.32.8.821, PMID: 15258107 [dostęp 2022-01-17] (ang.).
  • Paul Moayyedi, Daniel C. Sadowski, Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data?, „Canadian Journal of Gastroenterology”, 23 (4), 2009, s. 251–252, DOI: 10.1155/2009/868946, PMID: 19373416, PMCID: PMC2711671 [dostęp 2022-01-17] (ang.).

tropicalgastro.com

worldcat.org